Recent technological advancements, such as prostate-specific membrane antigen (PSMA) based PSMA-PET/CT, have been endorsed by the European Association of Urology (EAU) as essential diagnostic tools for PCa, offering superior accuracy in identifying tumors and metastatic lymph nodes (4). The gene discussed is FOLH1; the disease is posterior cortical atrophy.